
Low Anterior Resection (LAR) is a major surgical procedure used to treat cancers located in the upper or middle parts of the rectum. The primary goal is to remove the cancerous section while preserving the anal sphincter, allowing for the maintenance of normal bowel continuity and avoiding a permanent stoma. The integration of Total Mesorectal Excision (TME) and robotic-assisted precision has made LAR the standard of care for sphincter-preserving rectal surgery.
Mid-to-Upper Rectal Tumors: When the malignancy is located typically 5 cm or more from the anal verge.
Sphincter Preservation: When the cancer has not invaded the anal sphincter muscles, allowing for a safe reconnection.
Clear Distal Margins: When imaging confirms enough healthy tissue remains below the tumor to create a secure internal connection.
Response to Chemoradiotherapy: For patients who have undergone neoadjuvant treatment to shrink a tumor into a resectable range.
Non-Metastatic Localized Disease: When the primary goal is curative intent through the complete removal of the rectum and surrounding lymph nodes.
Robotic-Assisted LAR: The 2026 preferred method for mid-to-low tumors. The robotic platform’s 3D high-definition vision and "wristed" instruments provide superior precision in the narrow male or female pelvis.
Laparoscopic Surgery: A minimally invasive "keyhole" approach that offers faster recovery and less pain than open surgery.
Open Surgery: Performed via a midline abdominal incision; reserved for very large tumors or complex cases involving multiple organ involvements.
Total Mesorectal Excision (TME): A meticulous technique used during LAR to remove the rectum along with the intact fatty envelope (mesorectum) containing the lymph nodes, significantly reducing recurrence.
Ultra-Low LAR: A specialized variation for tumors very close to the pelvic floor, where the connection is made almost at the level of the anal opening.
Anaesthesia: The procedure typically takes 3 to 6 hours under general anaesthesia.
Mobilization: The surgeon frees the sigmoid colon and rectum from the surrounding pelvic structures and critical nerves.
Vascular Control: The main artery supplying the rectum (Inferior Mesenteric Artery) is ligated to ensure a complete lymph node harvest.
Stapled Anastomosis: Specialized circular staplers are used to connect the healthy colon to the remaining rectal stump.
Air-Leak Testing: A routine safety check is performed during surgery to ensure the new connection is airtight and watertight.
Defunctioning Ileostomy: A temporary stoma is often created to "divert" stool, allowing the internal connection (anastomosis) to heal without stress for 2–3 months.
Neoadjuvant Therapy: Completing a 5-week course of chemoradiotherapy to shrink the tumor and "sterilize" the surgical field.
Mechanical Bowel Prep: A thorough clearing of the bowels the day before surgery to minimize infection risks.
Pelvic Floor Baseline: Consulting with a physiotherapist to establish pelvic muscle strength before surgery.
Stoma Education: Meeting with a Wound, Ostomy, and Continence (WOC) nurse to mark a potential stoma site and learn about temporary bag management.
Nutritional Loading: Adhering to a "pre-habilitation" diet to maintain protein levels, which is crucial for internal healing.
Pelvic MRI: The "gold standard" for staging rectal cancer and determining the exact distance of the tumor from the sphincter.
Endorectal Ultrasound: To assess the depth of tumor invasion into the rectal wall layers.
CEA Blood Test: To establish a baseline tumor marker level for post-operative monitoring.
Rigid Proctoscopy: A physical measurement of the tumor's height to plan the exact level of the resection.
CT Chest/Abdomen/Pelvis: To ensure the cancer has not spread to the liver or lungs before proceeding with major pelvic surgery.
Hospital Stay: Usually 4 to 7 days, focusing on the return of bowel function and pain management.
Anastomotic Leak: A serious complication (5–10% risk) where the internal connection fails; 2026 protocols use early CRP monitoring to detect this before symptoms appear.
LARS (Low Anterior Resection Syndrome): A cluster of symptoms including urgency, frequency, and "clustering" of bowel movements that typically improves over 6–12 months.
Pelvic Nerve Preservation: While robotic surgery reduces risk, some may experience temporary urinary or sexual dysfunction due to the proximity of the autonomic nerves.
Low-Residue Diet: A temporary post-operative diet low in fiber to allow the bowel connections to heal without irritation.
Lower Recurrence Rates: TME technique combined with neoadjuvant therapy has reduced local recurrence to below 5% in specialized centers.
Permanent Stoma Avoidance: Modern LAR techniques allow over 90% of mid-rectal cancer patients to avoid a permanent colostomy.
Robotic Precision: 2026 data shows that robotic LAR leads to better preservation of sexual and bladder function compared to traditional methods.
Enhanced Recovery (ERAS): Specialized protocols allow patients to walk and eat sooner, reducing the risk of blood clots and pneumonia.
Biologically Tailored Care: Integration of tumor genetic profiling helps determine if a patient needs further "mop-up" chemotherapy after a successful LAR.